Kute Vivek B, Patel Himanshu V, Shah Pankaj R, Modi Pranjal R, Shah Veena R, Rizvi Sayyed J, Pal Bipin C, Shah Priya S, Wakhare Pavan S, Shinde Saiprasad G, Ghodela Vijay A, Varyani Umesh T, Patel Minaxi H, Trivedi Varsha B, Trivedi Hargovind L
Vivek B Kute, Himanshu V Patel, Pankaj R Shah, Priya S Shah, Pavan S Wakhare, Saiprasad G Shinde, Vijay A Ghodela, Umesh T Varyani, Hargovind L Trivedi, Department of Nephrology and Clinical Transplantation, Institute of Kidney Diseases and Research Center, Dr HL Trivedi Institute of Transplantation Sciences (IKDRC-ITS), Ahmedabad 380016, India.
World J Transplant. 2017 Feb 24;7(1):64-69. doi: 10.5500/wjt.v7.i1.64.
To report the first international living related two way kidney paired donation (KPD) transplantation from India which occurred on 17 February 2015 after legal permission from authorization committee.
Donor recipient pairs were from Portugal and India who were highly sensitized and ABO incompatible with their spouse respectively. The two donor recipient pairs had negative lymphocyte cross-matching, flow cross-match and donor specific antibody in two way kidney exchange with the intended KPD donor. Local KPD options were fully explored for Indian patient prior to embarking on international KPD.
Both pairs underwent simultaneous uneventful kidney transplant surgeries and creatinine was 1 mg/dL on tacrolimus based immunosuppression at 11 mo follow up. The uniqueness of these transplantations was that they are first international KPD transplantations in our center.
International KPD will increases quality and quantity of living donor kidney transplantation. This could be an important step to solving the kidney shortage with additional benefit of reduced costs, improved quality and increased access for difficult to match incompatible pairs like O blood group patient with non-O donor and sensitized patient. To the best of our knowledge this is first international KPD transplantation from India.
报告2015年2月17日在获得授权委员会合法许可后印度首例国际亲属活体双向肾移植配对（KPD）。
供受者对分别来自葡萄牙和印度，均高度致敏且与各自配偶ABO血型不相容。这两对供受者在与预期的KPD供者进行双向肾交换时，淋巴细胞交叉配型、流式交叉配型和供者特异性抗体均为阴性。在开展国际KPD之前，为印度患者充分探索了当地的KPD方案。
两对均顺利进行了同期肾移植手术，在11个月的随访中，基于他克莫司的免疫抑制治疗下肌酐水平为1mg/dL。这些移植的独特之处在于它们是我们中心首例国际KPD移植。
国际KPD将提高活体供肾移植的质量和数量。这可能是解决肾源短缺问题的重要一步，还有降低成本、提高质量以及增加难以匹配的不相容对（如O型血患者与非O型供者以及致敏患者）的可及性等额外益处。据我们所知，这是首例来自印度的国际KPD移植。
